Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this randomized clinical trial is to determine if lowering homocysteine levels
in renal transplant recipients with a multivitamin will reduce the occurrence of
cardiovascular disease outcomes.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator:
Office of Dietary Supplements (ODS)
Treatments:
Folic Acid Hydroxocobalamin Pantothenic Acid Pyridoxal Pyridoxine Vitamin B 12 Vitamin B 6 Vitamin B Complex Vitamins